Fig 1.
Flow diagram demonstrating patient and isolate selection for initial assessment of mexZ and lasR sequence diversity and antibiotic susceptibility.
Fig 2.
Flow diagram showing patients included in the two cross-sectional surveys for ‘M3L7’ AUST-02 subtype at TPCH.
Table 1.
Antibiotic susceptibilities of the M3L7 AUST-02 subtype compared with other non-M3L7 AUST-02 subtypes.
Table 2.
Summary of longitudinal within-patient changes involving shared and unique Pseudomonas aeruginosa strains, including their subtypesa.
Fig 3.
Clinical outcome of 166 TPCH adult patients within 3-years of participating in the 2007–2009 survey.
Table 3.
Baseline clinical characteristics of the 166 patients with cystic fibrosis and Pseudomonas aeruginosa infection from The Prince Charles Hospital surveyed in 2007–2009. a
Fig 4.
Kaplan-Meier survival analysis comparing unadjusted time to death or lung transplantation for 13 patients with M3L7, 57 with non-M3L7 AUST-02 and 96 patients with non-AUST-02 Pseudomonas aeruginosa strains.
Table 4.
Disease progression and treatment burden (2007–2009 and 2011) by Pseudomonas aeruginosa strain and subtype groupings.